NVIDIA Announces BioNeMo Agent Toolkit — Tools for Agents to Accelerate Scientific Discovery
News Summary:
- Industry and research leaders including Dassault Systèmes, Databricks, Lilly, OpenAI, Schrödinger, Snowflake, the UW Medicine Institute for Protein Design and dozens others are adopting, and Anthropic and OpenAI are integrating, NVIDIA BioNeMo Agent Toolkit to bring agentic life sciences workflows to researchers and scientists.
- NVIDIA BioNeMo Agent Toolkit — including NVIDIA Nemotron, NemoClaw, OpenShell and BioNeMo — gives agents accelerated life sciences tools spanning biology, chemistry, genomics and drug discovery.
- New NVIDIA BioNeMo tools give agents the context and know-how to execute scientific computing — improving accuracy, task completion and token efficiency.
SAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- BIO -- NVIDIA today announced NVIDIA BioNeMo Agent Toolkit, which provides domain-specific tools and skills for the agentic life sciences era.
Including more than a decade’s worth of NVIDIA life sciences libraries, tools and open models, the toolkit enables AI agents, scientists and labs to work together by gathering evidence, reasoning across findings, running computational experiments and recommending the next best steps to accelerate discovery.
It gives any agent or AI platform — from general-purpose assistants to specialized scientific agents, software platforms and in-house biopharma systems — the tools needed to synthesize and summarize scientific knowledge, call models, evaluate results, reason and execute next actions.
The toolkit includes NVIDIA BioNeMo™ and is powered by NVIDIA NIM™ microservices, NVIDIA Parabricks®, NVIDIA NeMo™ and NVIDIA Nemotron™ technologies, along with accelerated computing and skills — providing an open and trusted foundation for agentic life sciences.
More than 50 leading companies are already using it to advance scientific discovery, tapping into agent-callable skills for tasks including protein structure prediction, molecular docking, generative chemistry, genomic analysis, protein design and biomarker discovery.
"Frontier models are the brains. BioNeMo is the scientific toolbox. Together, they give AI agents the skills of a PhD research assistant and the speed of a supercomputer," said Jensen Huang, founder and CEO of NVIDIA. "For the first time, researchers can build AI agents that understand scientific knowledge, use scientific tools and execute scientific workflows. This is a new way to do science — one that can dramatically accelerate discovery across biology, chemistry, genomics and medicine."
Open model and research organizations — including the Arc Institute, Open Molecular Software Foundation and the University of Washington’s Institute for Protein Design (IPD) — are working with NVIDIA to use BioNeMo to advance frontier models and make them more accessible through agent-ready workflows. The IPD collaboration has accelerated runtimes for state-of-the-art biodesign models like RosettaFold3, resulting in 2x faster performance than the prior-generation model, and many additional applications to accelerate protein design efforts are ongoing, giving researchers tools at a scale and cost not before possible.
"Every tool we’ve built for protein design is only as powerful as the scientists who can efficiently access it," said David Baker, professor of biochemistry at the University of Washington School of Medicine and director of the Institute for Protein Design. "The next leap in science won’t come from a single discovery; it will come from the speed of iterative designs and agents that can repeatedly reason through the complexity of biology at a speed humans never could."
Agent-Ready Tools and Skills for Life Sciences
Life sciences is one of the world’s most important scientific frontiers, with global scientific R&D reaching $3.8 trillion and annual pharmaceutical budgets approaching $300 billion.
Agentic workflows can help the industry iterate faster while reducing costs and maximizing the probability of success. With the toolkit allowing developers to transform general-purpose agents into life sciences agents in minutes, researchers can run experiments faster, continuously learn from results and close the loop between hypothesis and discovery, with some companies extending this iteration into physical labs.
A general-purpose agent can struggle to navigate scientific workflows efficiently, needing to infer the correct tools, inputs, outputs and biological meaning along the way. With BioNeMo Agent Toolkit, agents can call the right tools, interpret results more accurately and gain scientific insights faster and more reliably.
NVIDIA is optimizing the entire BioNeMo platform by turning libraries, models and frameworks into agent-callable tools.
This includes harnessing NVIDIA Agent Toolkit technologies such as NVIDIA Nemotron open models for the reasoning foundation, the NVIDIA NeMo RL library for reinforcement learning and NVIDIA NemoClaw™ blueprints for secure, private agents that can reason across tasks, call tools and interact with data continuously.
NVIDIA NIM microservices help agents call models and perform tasks. The NVIDIA OpenShell™ runtime provides a controlled executable environment.
The toolkit’s components enable agents to complete workflows such as:
- Virtual Screening: Agents can help researchers identify small-molecule drug candidates by generating and screening compounds, docking them to a target, predicting binding strength and filtering for drug-like properties. Then, the agent can output which candidates should be prioritized, compressing screening timelines from days to minutes.
- Genomic Analysis and Target Discovery: Agents can help researchers transform raw sequencing data into prioritized genetic insights and biological targets. NVIDIA Parabricks accelerates alignment and variant calling, while genomic foundation models score variant effects and the agent ranks the most disease-relevant candidates for further study.
- Protein Binder Design: Agents can help researchers design and validate candidates computationally before work begins, compressing traditionally labor-intensive design work.
- Deep Biomedical Research: Agents connect real-world data to reasoning models to improve the efficiency and accuracy of various scientific and clinical development processes, including literature review, protocol generation, clinical trial screening and pharmacovigilance with the NVIDIA Biomedical AI-Q Research Agent.
- Medical Imaging Analysis: Agents can help researchers process, segment, synthesize and reason over medical imaging data to support biomarker discovery, accelerating evidence generation across research workflows.
Life Sciences Ecosystem Builds With NVIDIA BioNeMo
Companies across the technology and life sciences ecosystem are using the toolkit to advance agentic workflows.
Frontier labs and scientific agent builders including Anthropic, Edison Scientific, Lila Sciences, OpenAI and Owkin are integrating with BioNeMo to help agents move from answering questions to completing scientific work. NVIDIA accelerated models and analysis libraries help shorten the time from hypothesis to insight.
Scientific data and workflow platforms from Benchling, Certara, Databricks, Snowflake and Seqera are using BioNeMo Agent Toolkit to connect data systems with AI-powered science. BioNeMo skills can help agents query biological and chemical datasets, prepare model-ready inputs, launch reproducible workflows, analyze outputs and return insights directly within the platforms scientists and data teams already use daily.
Diagnostics and pharmaceutical companies including Lilly and Natera are using BioNeMo Agent Toolkit to scale repeatable agentic workflows across discovery, translational research and clinical insight.
AI-native biology companies including Boltz, Basecamp Research, Chai Discovery, Dyno, PerturbAI and Proxima have collaborated with NVIDIA to develop tools to accelerate model-powered therapeutic design workflows.
Computer-aided drug discovery software providers including Dassault Systèmes, Cadence (OpenEye) and Schrödinger are integrating the toolkit’s capabilities into scientific applications used across discovery teams. Then, agents can help orchestrate molecular generation, docking and prediction, turning computer-aided design platforms into systems where researchers can ask questions, launch analyses and identify next-best actions faster.
Lab instruments and automation companies including Automata, HighRes, Tecan, Thermo Fisher and autonomous data generation platform Medra are connecting systems with computational discovery powered by BioNeMo skills.
AI clouds and AI infrastructure companies including Baseten, Modal and Nebius are using the toolkit to help developers build life sciences workflows as reliable hosted services. By supporting BioNeMo skills and tools through scalable application programming interfaces, managed compute and production inference environments, these companies can help move agentic biology workflows from prototypes into accessible services for researchers and enterprises.
Availability
BioNeMo Agent Toolkit and skills are available now through the NVIDIA developer resources page and GitHub.
About NVIDIA
NVIDIA is the world leader in AI and accelerated computing.
For further information, contact:
Janette Ciborowski
Corporate Communications
NVIDIA Corporation
press@nvidia.com
Certain statements in this press release including, but not limited to, statements as to: for the first time, researchers being able to build AI agents that understand scientific knowledge, use scientific tools and execute scientific workflows; expectations with respect to growth, performance, availability, and benefits of NVIDIA’s products, services and technologies, and related trends and drivers; expectations with respect to NVIDIA’s third party arrangements, including with its collaborators and partners; expectations with respect to technology developments, and related trends and drivers; projected market growth and trends; expectations with respect to AI and related industries; and other statements that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections based on management’s beliefs and assumptions and on information currently available to management and are subject to risks and uncertainties that could cause results to be materially different than expectations. Important factors that could cause actual results to differ materially include: global economic and political conditions; NVIDIA’s reliance on third parties to manufacture, assemble, package and test NVIDIA’s products; the impact of technological development and competition; development of new products and technologies or enhancements to NVIDIA’s existing products and technologies; market acceptance of NVIDIA’s products or NVIDIA’s partners’ products; design, manufacturing or software defects; changes in consumer preferences or demands; changes in industry standards and interfaces; unexpected loss of performance of NVIDIA’s products or technologies when integrated into systems; NVIDIA’s ability to realize the potential benefits of business investments or acquisitions; and changes in applicable laws and regulations, as well as other factors detailed from time to time in the most recent reports NVIDIA files with the Securities and Exchange Commission, or SEC, including, but not limited to, its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Copies of reports filed with the SEC are posted on the company’s website and are available from NVIDIA without charge. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, NVIDIA disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.
© 2026 NVIDIA Corporation. All rights reserved. NVIDIA, the NVIDIA logo, BioNeMo, NemoClaw, Nemotron, NVIDIA NeMo, NVIDIA NIM, NVIDIA OpenShell and Parabricks are trademarks and/or registered trademarks of NVIDIA Corporation in the U.S. and other countries. Other company and product names may be trademarks of the respective companies with which they are associated. Features, pricing, availability and specifications are subject to change without notice.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5ca024bb-1493-4542-96e6-7e98ec3c271c
